To date, only glucocorticoids have been shown to reduce mortality in COVID-19. Use of remdesivir was associated with reduced length of stay in hospitalized COVID-19 patients. A deadly second wave in Asian countries has caused increased demand and usage of remdesivir in these countries. However, there is limited data about its efficacy in patients with severe renal dysfunction or end-stage renal disease on dialysis.